Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




BRIC Countries Outperform Rest of the World in IVD Sales Growth

By LabMedica International staff writers
Posted on 27 Jun 2011
The rate of growth for diagnostic instrumentation, product, and reagent sales for Brazil, Russia, India, and China (dubbed the BRIC nations) is double the six percent growth rate projected for worldwide in vitro diagnostics (IVD) sales.

In BRIC nations IVD sales are expected to grow from US $2.9 billion in 2009 to $5 billion in 2014, which represents a compound annual growth rate (CAGR) of 12%. More...
The market in these countries is dominated by companies such as Roche (Basel, Switzerland), Abbott (Des Plaines, IL, USA), Siemens (Munich, Germany), and Beckman Coulter (Fullerton, CA, USA). Domestic companies such as Transasia (Mumbai, India), Horiba (Kyoto, Japan), and Mindray (Shenzhen, China) have taken the distribution of IVD products from urban areas to the rural areas in their respective markets. Incumbent companies tend to provide a host of routine tests.

It is expected that as the IVD demand in developing countries increases, there will be opportunities for rapid tests and advanced tests that are now emerging as local healthcare systems become more sophisticated.

A report from Kalorama Information (Rockville, MD, USA), publisher of research in medical markets, presents the challenges that BRIC countries face entering the IVD market. The report also explores the opportunities that specific developing countries offer to IVD companies. Kalorama attempts to add some realistic aspects of working in a foreign country that are more qualitative in nature.

A number of reports on the BRIC and emerging markets have been published. Most of these focus on quantitative data such as number of labs, hospitals, product registration regulations, and import taxes and conditions. Too many of them tend to present only a growth scenario without presenting the challenges the nations face.

Some of the same trends–growing middle class, mix of infectious and noncommunicable diseases, and government supported healthcare–are prevalent in many countries in Eastern Europe and Africa. Kalorama provides three non-BRIC nations: Turkey, Poland, and Nigeria as examples of where IVD may flourish in the future.

Author of the report, Shara Rosen, RT, MBA, commented, "It is now recognized that it's the low- and middle-income countries that face the greatest burden of chronic diseases such as diabetes, heart disease, and cancer. As markets in industrialized countries begin to mature, IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and a growing demand for quality medical care."

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services.

Related Links:

Kalorama Information


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.